The University of Chicago Header Logo

Connection

Mary Elizabeth Strek to Female

Back to Details
This is a "connection" page, showing publications Mary Elizabeth Strek has written about Female.
Mary Elizabeth Strek
Connection Strength
0.757
Female
  1. Evaluation of Pulmonary Fibrosis Outcomes by Race and Ethnicity in US Adults. JAMA Netw Open. 2023 03 01; 6(3):e232427.
    View in: PubMed
    Score: 0.044
  2. Characteristics and Prevalence of Domestic and Occupational Inhalational Exposures Across Interstitial Lung Diseases. Chest. 2021 07; 160(1):209-218.
    View in: PubMed
    Score: 0.038
  3. African-American race and mortality in interstitial lung disease: a multicentre propensity-matched analysis. Eur Respir J. 2018 06; 51(6).
    View in: PubMed
    Score: 0.032
  4. CT-Pathologic Correlation of Major Types of Pulmonary Fibrosis: Insights for Revisions to Current Guidelines. AJR Am J Roentgenol. 2018 May; 210(5):1034-1041.
    View in: PubMed
    Score: 0.031
  5. CT Features of the Usual Interstitial Pneumonia Pattern: Differentiating Connective Tissue Disease-Associated Interstitial Lung Disease From Idiopathic Pulmonary Fibrosis. AJR Am J Roentgenol. 2018 Feb; 210(2):307-313.
    View in: PubMed
    Score: 0.030
  6. Asthma Outcomes and Management During Pregnancy. Chest. 2018 02; 153(2):515-527.
    View in: PubMed
    Score: 0.030
  7. De Novo Development of Bronchiectasis in Patients With Hematologic Malignancy. Chest. 2017 09; 152(3):683-685.
    View in: PubMed
    Score: 0.030
  8. CT findings associated with survival in chronic hypersensitivity pneumonitis. Eur Radiol. 2017 Dec; 27(12):5127-5135.
    View in: PubMed
    Score: 0.030
  9. CT Findings, Radiologic-Pathologic Correlation, and Imaging Predictors of Survival for Patients With Interstitial Pneumonia With Autoimmune Features. AJR Am J Roentgenol. 2017 Jun; 208(6):1229-1236.
    View in: PubMed
    Score: 0.029
  10. Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease. Respir Med. 2016 12; 121:117-122.
    View in: PubMed
    Score: 0.028
  11. Characterisation of patients with interstitial pneumonia with autoimmune features. Eur Respir J. 2016 06; 47(6):1767-75.
    View in: PubMed
    Score: 0.027
  12. Predictors of survival in coexistent hypersensitivity pneumonitis with autoimmune features. Respir Med. 2016 05; 114:53-60.
    View in: PubMed
    Score: 0.027
  13. Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease. Pulm Pharmacol Ther. 2016 Feb; 36:46-52.
    View in: PubMed
    Score: 0.027
  14. Improving asthma management: time for an action plan. Chest. 2012 Nov; 142(5):1085-1087.
    View in: PubMed
    Score: 0.021
  15. Bronchiectasis in a diverse US population: effects of ethnicity on etiology and sputum culture. Chest. 2012 Jul; 142(1):159-167.
    View in: PubMed
    Score: 0.021
  16. Autoimmune-featured interstitial lung disease: a distinct entity. Chest. 2011 Nov; 140(5):1292-1299.
    View in: PubMed
    Score: 0.019
  17. Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression. Respir Res. 2023 May 31; 24(1):141.
    View in: PubMed
    Score: 0.011
  18. Sex- and Race-Based Differences in the Treatment of Interstitial Lung Diseases in North America and Australasia. Chest. 2023 05; 163(5):1156-1165.
    View in: PubMed
    Score: 0.011
  19. High-titer rheumatoid factor seropositivity predicts mediastinal lymphadenopathy and mortality in rheumatoid arthritis-related interstitial lung disease. Sci Rep. 2021 11 24; 11(1):22821.
    View in: PubMed
    Score: 0.010
  20. Hospitalizations in patients with idiopathic pulmonary fibrosis. Respir Res. 2021 Sep 30; 22(1):257.
    View in: PubMed
    Score: 0.010
  21. Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer Cells. Am J Respir Crit Care Med. 2021 07 15; 204(2):197-208.
    View in: PubMed
    Score: 0.010
  22. Detection and Early Referral of Patients With Interstitial Lung Abnormalities: An Expert Survey Initiative. Chest. 2022 02; 161(2):470-482.
    View in: PubMed
    Score: 0.010
  23. COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia. Clin Pharmacol Ther. 2021 03; 109(3):688-696.
    View in: PubMed
    Score: 0.009
  24. Gender equity in interstitial lung disease. Lancet Respir Med. 2020 09; 8(9):842-843.
    View in: PubMed
    Score: 0.009
  25. CPAP Adherence, Mortality, and Progression-Free Survival in Interstitial Lung Disease and OSA. Chest. 2020 10; 158(4):1701-1712.
    View in: PubMed
    Score: 0.009
  26. Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis. Chest. 2020 10; 158(4):1526-1534.
    View in: PubMed
    Score: 0.009
  27. Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2020 03 01; 201(5):564-574.
    View in: PubMed
    Score: 0.009
  28. Circulating Plasma Biomarkers of Progressive Interstitial Lung Disease. Am J Respir Crit Care Med. 2020 01 15; 201(2):250-253.
    View in: PubMed
    Score: 0.009
  29. Diagnostic test interpretation and referral delay in patients with interstitial lung disease. Respir Res. 2019 Nov 12; 20(1):253.
    View in: PubMed
    Score: 0.009
  30. Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2019 07 15; 200(2):199-208.
    View in: PubMed
    Score: 0.009
  31. Prevalence and Clinical Significance of Antineutrophil Cytoplasmic Antibodies in North American Patients With Idiopathic Pulmonary Fibrosis. Chest. 2019 10; 156(4):715-723.
    View in: PubMed
    Score: 0.008
  32. Computed Tomography Honeycombing Identifies a Progressive Fibrotic Phenotype with Increased Mortality across Diverse Interstitial Lung Diseases. Ann Am Thorac Soc. 2019 05; 16(5):580-588.
    View in: PubMed
    Score: 0.008
  33. Telomere length and genetic variant associations with interstitial lung disease progression and survival. Eur Respir J. 2019 04; 53(4).
    View in: PubMed
    Score: 0.008
  34. Prognosticating Outcomes in Interstitial Lung Disease by Mediastinal Lymph Node Assessment. An Observational Cohort Study with Independent Validation. Am J Respir Crit Care Med. 2019 03 15; 199(6):747-759.
    View in: PubMed
    Score: 0.008
  35. Anti-RNA binding protein positivity in idiopathic interstitial pneumonia. Respir Med. 2019 01; 146:23-27.
    View in: PubMed
    Score: 0.008
  36. Underreporting of Interstitial Lung Abnormalities on Lung Cancer Screening Computed Tomography. Ann Am Thorac Soc. 2018 06; 15(6):764-766.
    View in: PubMed
    Score: 0.008
  37. N-acetylcysteine exposure is associated with improved survival in anti-nuclear antibody seropositive patients with usual interstitial pneumonia. BMC Pulm Med. 2018 Feb 08; 18(1):30.
    View in: PubMed
    Score: 0.008
  38. Phenotypic Clusters Predict Outcomes in a Longitudinal Interstitial Lung Disease Cohort. Chest. 2018 02; 153(2):349-360.
    View in: PubMed
    Score: 0.008
  39. Myositis-associated Interstitial Lung Disease: Predictors of Failure of Conventional Treatment and Response to Tacrolimus in a US Cohort. J Rheumatol. 2017 Nov; 44(11):1612-1618.
    View in: PubMed
    Score: 0.007
  40. Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 Nov; 102(5):859-869.
    View in: PubMed
    Score: 0.007
  41. Interstitial Pneumonia With Autoimmune Features: Value of Histopathology. Arch Pathol Lab Med. 2017 Jul; 141(7):960-969.
    View in: PubMed
    Score: 0.007
  42. Interstitial pneumonia with autoimmune features: Clinical, radiologic, and histological characteristics and outcome in a series of 57 patients. Respir Med. 2017 02; 123:56-62.
    View in: PubMed
    Score: 0.007
  43. Response. Chest. 2016 Feb; 149(2):600-601.
    View in: PubMed
    Score: 0.007
  44. TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2015 Dec 15; 192(12):1475-82.
    View in: PubMed
    Score: 0.007
  45. A functional genomic model for predicting prognosis in idiopathic pulmonary fibrosis. BMC Pulm Med. 2015 Nov 21; 15:147.
    View in: PubMed
    Score: 0.007
  46. Thyroid Disease Is Prevalent and Predicts Survival in Patients With Idiopathic Pulmonary Fibrosis. Chest. 2015 Sep; 148(3):692-700.
    View in: PubMed
    Score: 0.007
  47. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29; 370(22):2083-92.
    View in: PubMed
    Score: 0.006
  48. Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014 Apr 18; 31(1):46-54.
    View in: PubMed
    Score: 0.006
  49. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013 May 07; 158(9):641-9.
    View in: PubMed
    Score: 0.006
  50. Barriers to optimal palliative care of lung transplant candidates. Chest. 2013 Mar; 143(3):736-743.
    View in: PubMed
    Score: 0.005
  51. Prevalence of hiatal hernia by blinded multidetector CT in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2012 Feb; 39(2):344-51.
    View in: PubMed
    Score: 0.005
  52. Clinical characteristics of patients with anti-Jo-1 antibodies: a single center experience. J Clin Rheumatol. 2009 Aug; 15(5):254-5.
    View in: PubMed
    Score: 0.004
  53. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest. 2006 Jan; 129(1):56-66.
    View in: PubMed
    Score: 0.003
  54. Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer. Respir Med. 2001 Jan; 95(1):1-4.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.